PureTech subsidiary licences microbiome-based therapy

PureTech Health subsidiary Commense Inc has licensed a microbiome-based therapy to prevent asthma and other allergic diseases from the University of British Columbia.

"This live biotherapeutic product bolsters Commense's pipeline of novel therapeutic programs designed to nurture a healthy microbiome early in life," the company said.